The Caris Precision Oncology Alliance has brought together academic institutions and community practices with the goal of performing research and exchanging evidence and ideas for new types of tests, said W. Michael Korn, MD.
The Caris Precision Oncology Alliance has brought together academic institutions and community practices with the goal of performing research and exchanging evidence and ideas for new types of tests, said W. Michael Korn, MD, professor of medicine in the Division of Hematology/Oncology at the University of California, San Francisco, and chief medical officer of Caris Life Sciences.
Transcript
What is the purpose of the Caris Precision Oncology Alliance? How do members collaborate?
There is actually some overlap with what QCCA [Quality Cancer Care Alliance] is doing, and I think it's an extremely important initiative. So, what this is a now pretty large group of mostly academic institutions that are affiliated with Caris Life Sciences—in terms of being affiliated with a goal of performing research together, with the goal of exchanging evidence on how to interpret our findings, and exchange ideas and express needs for new types of tests.
So, there are now over 40 institutions all across the United States, including, I believe, currently 11 NCI [National Cancer Institute]–designated Comprehensive Cancer Centers. So, there's a lot of intellectual power now coming together. It's a very dynamic organization, and we perform many, many research projects in collaboration with these institutions. And it's really has been tremendously beneficial for both sides.
There are also some more community-oriented institutions [that are a] part of that. And I think that's where the overlap really exists. For there are, you know, institutions that have affiliated practices in their surrounding. And so, I think there's a real overlap, and we recognize that understanding what's happening in kind of an oncologist’s practices, not academic [medical centers], is extremely important, because that's the vast majority of [where] patients are being treated.
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
What the Updated Telephone Consumer Protection Act Rules Mean for Health Care Messaging
April 4th 2025As new Federal Communications Commission rules take effect April 11, 2025, mPulse CEO Bob Farrell explains how health organizations can stay compliant while building patient trust through transparency and personalized engagement.
Read More
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
April 4th 2025Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Read More